ResMed Inc. (RMD.AX)
Chart Events
Performance Outlook
| Previous Close | 34.62 |
| Open | 33.29 |
| Bid | 33.51 x 51100 |
| Ask | 33.86 x 25600 |
| Day's Range | 32.59 - 33.88 |
| 52 Week Range | 27.37 - 40.79 |
| Volume | |
| Avg. Volume | 1,260,550 |
| Market Cap | 49.652B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 43.57 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.24 (0.69%) |
| Ex-Dividend Date | May 11, 2022 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RMD.AX
Related Research
- Benzinga
Competitor Recall Continues To Show Opportunities For ResMed
ResMed Inc (NYSE: RMD) posted Q4 sales of $914.7 million, +4% Y/Y (+8% on a constant currency basis), beating the consensus of $912.97 million. Adjusted EPS reached $1.49, up from $1.35 a year ago. The company also increased its quarterly dividend to $0.44 from $0.42 per share. Keybanc reiterates the Overweight rating and price target of $276. The analyst says that after resetting near-term supply chain expectations, visibility appears to be increasing and management's tone seemed more optimisti
- Zacks
ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
- Motley Fool
ResMed (RMD) Q4 2022 Earnings Call Transcript
Joining me on the call today are our chief executive officer, Mick Farrell, and chief financial officer, Brett Sandercock. Following our prepared remarks, we will host a Q&A session, and Mick and Brett will be joined by Rob Douglas, president and chief operating officer, and David Pendarvis, chief administrative officer and global general counsel.
